Recombinant Vector Vaccine Market Set for Growth as Vaccine Innovation and Manufacturing Investment Accelerate

Recombinant Vector Vaccine Market Overview

The global Recombinant Vector Vaccine Market was valued at US$19.14 billion in 2023 and is projected to grow at a CAGR of 7.2% from 2024 to 2030, reaching approximately US$31.14 billion by 2030. Recombinant vector vaccines use engineered viral or bacterial vectors to deliver genetic material capable of stimulating an immune response. Rising prevalence of infectious diseases, increasing government vaccination programs and advances in molecular biology, immunology, genomics and genetic engineering are supporting market expansion. According to the MMR report, recombinant technologies can enable vaccines to be produced rapidly and at larger volumes, creating opportunities to address vaccine supply requirements. Growing research into emerging and re-emerging infectious diseases is also encouraging development of new vaccine platforms. Advances in genetic engineering, improved antigen delivery and growing investment in vaccine research are expected to create opportunities for manufacturers, biotechnology companies and research organizations through 2030.

* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/84021/

U.S. Market Trends and Investment

The United States remains a major center for vaccine research, manufacturing and biotechnology investment. In March 2025, Merck opened a $1 billion, 225,000-square-foot vaccine manufacturing facility in Durham, North Carolina, expanding domestic vaccine-production capacity. Merck said the investment was part of more than $12 billion invested in U.S. capital projects since 2018, with another $8 billion expected through 2028. In October 2025, the company reported that its 2025 U.S. manufacturing expansion included nearly $6 billion in announced projects across North Carolina, Delaware, Kansas and Virginia. Novartis also announced a $23 billion five-year investment in U.S. manufacturing and R&D infrastructure in April 2025, including 10 facilities and seven new facilities. These investments strengthen the country's vaccine and biologics manufacturing ecosystem and can support future development and commercialization of advanced vaccine platforms.

Market Segmentation: Recombinant Viral Vector Vaccines Lead

By vector, the recombinant viral vector vaccines segment holds the largest share of the global market and is expected to maintain its leading position through 2030. MMR attributes this position to the ability of recombinant viral vectors to stimulate strong cellular immune responses and combine different antigen-delivery approaches. Advances in immunology, molecular biology, genomics and proteomics are further supporting the development of viral-vector vaccine technologies. By disease type, the viral segment commands the largest market share, supported by the prevalence of viral infectious diseases and continuing vaccine-development requirements.

Recombinant Vector Vaccine Market, Key Players are:
1. Sanai
2. Pfizer Inc.
3. Novartis AG
4. Neuron Biotech
5. Merck and Company
6. GlaxoSmithKline plc.
7. CSL Limited
8. Biological E
9. Bharat Biotech
10. Serum Institute of India Private Limited
11. CNBG
12. Protein Science Corporation
13. Green Cross Corporation
14. Bayer AG

Competitive Analysis

MMR identifies Sanai, Pfizer Inc., Novartis AG, Neuron Biotech and Merck and Company among the key players in the Recombinant Vector Vaccine Market. Because the report does not provide individual company-share percentages on its public page, these companies are discussed as key players rather than assigned a fabricated market-share ranking.

Sanai: Sanai is included by MMR among the companies operating in the recombinant vector vaccine market. The broader expansion of recombinant vaccine research and increasing emphasis on advanced antigen-delivery technologies provide opportunities for companies developing vector-based vaccine platforms.

Pfizer Inc.: Pfizer continued to demonstrate large-scale vaccine manufacturing capabilities in 2025. By the end of 2025, the company reported delivering its three-billionth Prevnar dose and highlighted continued investment in technologies intended to make manufacturing faster, smarter and more sustainable. Its global production network remains an important platform for vaccine development and supply.

Novartis AG: Novartis announced its $23 billion U.S. manufacturing and R&D expansion in April 2025. The planned infrastructure includes seven new facilities and a new research hub in the San Diego area, increasing domestic capabilities for pharmaceutical manufacturing and research. Such investment can strengthen the broader biotechnology ecosystem supporting next-generation vaccine research.

Neuron Biotech: Neuron Biotech is identified by MMR as a key market participant. Its inclusion reflects the growing role of biotechnology companies in developing specialized vaccine technologies and responding to infectious-disease prevention requirements.

Merck and Company: Merck made one of the clearest vaccine-manufacturing investments in 2025 with the opening of its $1 billion North Carolina facility. The company also began construction of additional U.S. manufacturing projects, supporting expanded capacity for vaccines and biologics.

Regional Analysis

USA: North America is expected to command the largest regional share by 2030, supported by developed scientific infrastructure, high public awareness, pharmaceutical-company presence and continuous R&D investment.

UK: The UK benefits from a mature vaccine research ecosystem and established pharmaceutical industry. GSK's 2025 results showed continued investment in its vaccines portfolio, with vaccine sales increasing 9% in the second quarter of 2025.

Germany: Germany is an important European pharmaceutical and biotechnology manufacturing center. Its research infrastructure and established vaccine industry provide a foundation for recombinant and other advanced vaccine technologies.

France: France's pharmaceutical research capabilities, public-health infrastructure and established immunization programs provide opportunities for advanced vaccine development and manufacturing.

Japan: Japan's sophisticated biotechnology and pharmaceutical industries support vaccine research, clinical development and advanced manufacturing technologies, creating opportunities for recombinant vaccine platforms.

China: China's large population, expanding biotechnology sector and focus on infectious-disease prevention provide opportunities for recombinant vaccine development and manufacturing. MMR includes China among the principal Asia Pacific markets covered by the report.

Menstrual Cup Market https://www.maximizemarketresearch.com/market-report/menstrual-cup-market/213519/

Acute Myeloid Leukaemia Therapeutics Market https://www.maximizemarketresearch.com/market-report/acute-myeloid-leukaemia-therapeutics-market/213386/

Conclusion

The Recombinant Vector Vaccine Market is positioned for continued expansion as governments, pharmaceutical companies and biotechnology organizations strengthen preparedness against infectious diseases. The major growth opportunity lies in viral-vector innovation, genetic engineering, scalable manufacturing and improved antigen-delivery technologies. Increasing investment in domestic vaccine production, particularly in the United States, together with advances in molecular biology and biotechnology.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? sales@maximizemarketresearch.com